ENDOCYTE INC's ticker is ECYT and the CUSIP is 29269A102. A total of 97 filers reported holding ENDOCYTE INC in Q2 2016. The put-call ratio across all filers is 0.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $17,000 | +88.9% | 930 | -11.8% | 0.00% | – |
Q2 2018 | $9,000 | 0.0% | 1,055 | 0.0% | 0.00% | – |
Q1 2018 | $9,000 | +80.0% | 1,055 | 0.0% | 0.00% | – |
Q4 2017 | $5,000 | +400.0% | 1,055 | 0.0% | 0.00% | – |
Q3 2017 | $1,000 | -75.0% | 1,055 | -63.5% | 0.00% | – |
Q2 2017 | $4,000 | -42.9% | 2,890 | +0.9% | 0.00% | – |
Q1 2017 | $7,000 | +75.0% | 2,864 | +62.8% | 0.00% | – |
Q4 2016 | $4,000 | -33.3% | 1,759 | -3.6% | 0.00% | – |
Q3 2016 | $6,000 | 0.0% | 1,825 | 0.0% | 0.00% | – |
Q2 2016 | $6,000 | 0.0% | 1,825 | -7.6% | 0.00% | – |
Q1 2016 | $6,000 | -25.0% | 1,976 | -3.0% | 0.00% | – |
Q4 2015 | $8,000 | -11.1% | 2,038 | 0.0% | 0.00% | – |
Q3 2015 | $9,000 | -18.2% | 2,038 | -7.6% | 0.00% | – |
Q2 2015 | $11,000 | -21.4% | 2,206 | -2.8% | 0.00% | – |
Q1 2015 | $14,000 | 0.0% | 2,270 | +3.0% | 0.00% | – |
Q4 2014 | $14,000 | 0.0% | 2,204 | -3.1% | 0.00% | – |
Q3 2014 | $14,000 | -12.5% | 2,275 | -7.0% | 0.00% | – |
Q2 2014 | $16,000 | -50.0% | 2,445 | +84.3% | 0.00% | -100.0% |
Q1 2014 | $32,000 | +113.3% | 1,327 | -8.5% | 0.00% | – |
Q4 2013 | $15,000 | -31.8% | 1,451 | -10.8% | 0.00% | -100.0% |
Q3 2013 | $22,000 | – | 1,626 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VHCP Management II, LLC | 4,300,000 | $59,340,000 | 17.76% |
RA Capital Management | 5,649,884 | $77,968,000 | 5.06% |
Avoro Capital Advisors LLC | 5,695,200 | $78,594,000 | 3.03% |
Crosspoint Capital Strategies, LLC | 107,620 | $1,485,000 | 2.84% |
Ghost Tree Capital, LLC | 500,000 | $6,900,000 | 2.03% |
EMORY UNIVERSITY | 205,295 | $2,833,000 | 1.88% |
Asymmetry Capital Management, L.P. | 103,159 | $1,424,000 | 1.40% |
NEXTHERA CAPITAL LP | 596,000 | $8,225,000 | 1.27% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,324,299 | $32,075,000 | 1.13% |
PFM Health Sciences, LP | 4,068,608 | $56,147,000 | 0.88% |